EXPLEOSOL Q4 FY26 Earnings Call Transcript & Analysis
Operating Revenue (Q4 FY26) 2863 million (+12% YoY); Adjusted EBITDA Margin (Q4 FY26) 15.5% (−1% YoY); Total Income (Q4 FY26) 2989 million (+15% YoY). Q4 FY26 Operating Revenue up 11.9% YoY to INR 2,863 million.
Read full transcript & analysis